|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Lilly's_COVID-19_antibody_therapy
gptkb:Lilly's_COVID-19_antibody_treatment
|
|
gptkbp:activities
|
neutralizes SARS-Co V-2
neutralizes the spike protein
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:United_States
February 2021
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:can_be_used_with
|
gptkb:Bamlanivimab
|
|
gptkbp:clinical_trial
|
combination therapy
Phase 3
outpatient setting
monotherapy
published in 2021
NC T04427501
|
|
gptkbp:collaborations
|
gptkb:Research_Institute
|
|
gptkbp:contraindication
|
hypersensitivity reactions
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:developer
|
2020 to 2021
|
|
gptkbp:dosage_form
|
solution for infusion
700 mg
|
|
gptkbp:duration
|
single administration
|
|
gptkbp:education
|
informed consent required
|
|
gptkbp:effective_date
|
February 2021
|
|
gptkbp:frequency
|
single dose
|
|
gptkbp:future_plans
|
focus on long-term effects
|
|
gptkbp:healthcare
|
significant during pandemic
training on administration
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Etesevimab
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:interacts_with
|
none significant
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
reduces hospitalization risk
|
|
gptkbp:is_monitored_by
|
vital signs
|
|
gptkbp:is_used_for
|
gptkb:drug
treatment of COVID-19
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:Etesevimab_injection
gptkb:Etesevimab
|
|
gptkbp:pharmacokinetics
|
long half-life
binds to spike protein
|
|
gptkbp:population
|
adults and pediatric patients
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_access_to
|
limited availability in some countries
|
|
gptkbp:provides_information_on
|
gptkb:American_College_of_Physicians
CDC guidelines
based on emerging data
|
|
gptkbp:publishes
|
multiple peer-reviewed articles
|
|
gptkbp:receives_funding_from
|
government and private sources
|
|
gptkbp:regulatory_compliance
|
Emergency Use Authorization
|
|
gptkbp:research_focus
|
COVID-19 variants
|
|
gptkbp:safety_features
|
post-marketing surveillance
generally well tolerated
|
|
gptkbp:scholarships
|
available through Eli Lilly
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
fever
diarrhea
infusion reactions
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:supply_chain
|
critical for distribution
availability issues
managed by Eli Lilly
|
|
gptkbp:targets
|
gptkb:SARS-Co_V-2
|
|
gptkbp:traded_on
|
gptkb:Etesevimab
|
|
gptkbp:treatment
|
improved recovery rates
|
|
gptkbp:type_of_insurance
|
may vary by plan
|